Diversified Consumer Services
Company Overview of Emory University
Emory University is an educational that offers undergraduate and graduate courses in the fields of arts and sciences, medicine, theology, law, nursing, public health, and business. The institution was founded in 1836 and is based in Atlanta, Georgia.
201 Dowman Drive
Atlanta, GA 30322
Founded in 1836
Key Executives for Emory University
Chief Environmental Officer
Vice President for Global Health
Executive Vice President for Health Affairs
Compensation as of Fiscal Year 2016.
Emory University Key Developments
Emory University Announces Executive Changes, Effective September 1, 2016
Jun 3 16
The Emory University Board of Trustees announced that Claire E. Sterk has been selected as the university’s 20th president. She was elected by a unanimous vote of the trustees during its meeting in Atlanta. Sterk will assume the role on September 1, 2016. She will succeed James W. Wagner, who announced in September 2015 his intention to retire at the end of August 2016 after 13 years as president. Sterk has been a member of the Emory community since 1995, when she was appointed to the faculty of the Rollins School of Public Health. Claire E. Sterk was provost and executive vice president for academic affairs at Emory.
Cocrystal Pharma, Inc. Enters into Agreement with Duke University and Emory University to License Various Patents and Know-How
Feb 10 16
Cocrystal Pharma Inc. announced it has signed an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). This license agreement allows Cocrystal to develop and potentially commercialize a cure for HBVA and HPVA utilizing the underlying patents and technologies developed by the universities.
AIDS Healthcare Foundation Begins Legal Battle to Strip Gilead Sciences Inc of Patents on HIV/AIDS Drug Genvoya
Jan 27 16
AIDS Healthcare Foundation (AHF) is suing Gilead Sciences Inc, looking to persuade a California district court to invalidate patents on the company's HIV/AIDS drug Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide). Gilead has resorted to patent system manipulation and anti-competitive practices in its relentless pursuit of maximum profits. The lawsuit focuses on patents related to Tenofovir, one of the compounds included in Gilead's TAF-based oral regimen. As AHF notes in its court filing, Tenofovir was first synthesised more than three decades ago in the Czech Republic so it is anything but a new compound. AHF has also named Japan Tobacco Inc. and Emory University among the defendants, claiming they have assisted Gilead in its attempt to extend the patent exclusivity period for medicines containing Tenofovir. The pharma group has manipulated the system by signing a licensing agreement with Japan Tobacco and using a pre-existing patent licensing agreement with Emory University as a way of preventing potential rival entry into the market and stifling competition. AHF has sustained direct damage as a result of Gilead's actions because the organisation has spent millions of dollars on Gilead drugs last year alone. AHF filed a complaint against Gilead with the US Food and Drug Administration (FDA), alerting the regulator that the company is promoting off-label use of its HIV/AIDS therapy Truvada. In a letter sent to FDA Acting Commissioner Stephen Ostroff, the organisation drew his attention to the fact that Gilead is among the sponsors of a video advertisement that promotes the situational use of Truvada for pre-exposure prophylaxis to prevent HIV infection. In this way, Gilead is giving viewers the wrong impression they can safely and effectively use Truvada on a situational basis although the drug has not been approved by the FDA for use in such way.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries